What are the risks of investing in NUVL?
N
What are the risks of investing in NUVL?
🦉
Nuvalent, Inc. (NUVL)
Company Overview
Sector / IndustryHealthcare / Biotechnology
CEOJames R. Porter
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and...
Key Executives
| Name | Title |
|---|---|
| Alex Balcom | Chief Financial Officer & Treasurer |
| Benjamin Lane | Chief Technical Operations Officer |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications |
| Christopher D. Turner | Chief Medical Officer |
| Darlene Noci | Chief Development Officer |
| Deborah Ann Miller | Chief Legal Officer & Secretary |
Financial Health
Risk Assessment
Weather Score0/100
RegimeN/A